Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis
Obesity · 2025-10 · 33 (10) · 1845-1848
DOI: 10.1002/oby.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 13.08.2025. Verfasst von Arpan Mohanty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Obesity, Liver Cirrhosis, Mass Screening. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Objective
The study aimed to compare the cost‐effectiveness of various strategies for screening for MASLD‐related advanced hepatic fibrosis (fibrosis stage > 2) using the fibrosis‐4 index (FIB‐4) and liver stiffness measurement (LSM) by transient elastography (TE) in persons with obesity.
Methods
We created a decision‐analytic model comparing three screening strategies: no screening, TE, and FIB‐4 followed by TE. We used a Markov transition model to track liver state, with prevalence and transition probabilities specific to the population with obesity. If MASLD was detected, patients were treated with resmetirom.
Results
We found an incremental cost‐effectiveness ratio (ICER) of $234,781 (95% CI: $232,581, $235,608) when comparing TE to no screening with a 10‐year interval. We note the ICER of $234,673 (95% CI: $234,033, $235,072) when comparing TE to FIB‐4+TE. In multivariate simulations, we found no screening was most likely to be cost‐effective for willingness‐to‐pay for QALY below approximately $250,000.
Conclusions
Our results suggest routine screening for MASLD in obesity clinics is not cost‐effective with resmetirom as the available treatment. A prescreening with FIB‐4 before TE did not increase economic efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
- Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
ORCID-Profile: Arpan Mohanty, Yin Wang
Förderung
- Gilead Sciences
Zitieren
APA
Mohanty, A., Wang, Y., & Stoecker, C. (2025). Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity, 33(10), 1845-1848. https://doi.org/10.1002/oby.70005
Vancouver
Mohanty A, Wang Y, Stoecker C. Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity. 2025;33(10):1845-1848. doi:10.1002/oby.70005
BibTeX
@article{Mohanty2025,
author = {Mohanty, Arpan and Wang, Yin and Stoecker, Charles},
title = {Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis},
journal = {Obesity},
year = {2025},
volume = {33},
number = {10},
pages = {1845--1848},
doi = {10.1002/oby.70005}
}
EUVIMED